iNtODEWORLD | Our research is committed to finding effective treatment for life-threatening infectious diseases.
15234
home,page,page-id-15234,page-template,page-template-full_width,page-template-full_width-php,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive

iNtODEWORLD

A Game Changer in Antibacterial Drugs for Superbugs and Persister Cells

We are committed to finding effective treatment for life-threatening infectious diseases.

maintopban1

A Game Changer in Antibacterials Treatment for Gram-negative bacteria, Ultimate Target of N-Rephasin® Technology

maintopban2

Eco-friendly, no Side-effects, Unique mode of action. Bacteriophages and Antibiotic Resistance in Bacteria

maintopban3

Opening a New Era in Anti-Fugal Agents. A New Type of Antifungal Agent, iN-EYD34

maintopban4

New Generation of Heme-Iron (Porphyrin-Fe) Novel concept iron deficiency anemia therapeutic agent

iNtRON Biotechnology, Inc.

iNtRON Bio has been focusing on the R&D investment since its foundation and accelerates development speed after the IPO in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.

INSIDE iNtRON

  • iNtRON Biotechnology and Estech Pharma today announced that they have entered into the collaboration agreement on eHeme (engineered Heme) technology development. According to iNtRON Bio, two companies will make an investment together in the bio and chemical production of eHeme based on the iNtRON Bio’s relevant patents.......

  • iNtRON Biotechnology held the corporate presentation for private and institutional investors on February 19, 2019. The purpose of the corporate presentation was to increase shareholders’ understanding about the company and investment value. During the corporate presentation, Seong Jun Yoon, CEO & Founder, made a presentation regarding......

  • Roivant plans to initiate Phase 2 clinical trial in 2019 Agreement includes option to in-license additional anti-Gr(+) programs   Roivant Sciences and iNtRON Biotechnology today announced that they have entered into a global licensing agreement for SAL200, a novel investigational biologic for the treatment of......

See All
seh

PIPELINES

iNtRON Bio has been focusing on the R&D investment since its foundation and accelerate development speed after the IPD in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.

iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.
PGlmcmFtZSB3aWR0aD0iNzAwIiBoZWlnaHQ9IjM5NCIgc3JjPSJodHRwczovL3d3dy55b3V0dWJlLmNvbS9lbWJlZC81UDMxdTh6emF6az9yZWw9MCIgZnJhbWVib3JkZXI9IjAiIGFsbG93PSJhdXRvcGxheTsgZW5jcnlwdGVkLW1lZGlhIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+